Michelle Glass

Michelle Glass is a New Zealand pharmacology academic. She is currently a full professor and Head of the Department of Pharmacology & Toxicology at the University of Otago.[1]

Michelle Glass
Alma materUniversity of Auckland
Scientific career
FieldsPharmacology of cannabinoid receptors
InstitutionsUniversity of Auckland, University of Otago
Thesis

Career

Since a 1994 PhD titled 'Receptor alterations in human neuro-degenerative diseases' at the University of Auckland, she has worked at both the University of Auckland and the University of Otago, rising to full professor.[2][1]

Glass's primary work has been on cannabinoids and they have received multiple grants for the work[3][4] and considerable press attention.[5][6][7][8] She has also been involved in a documentary 'Mum, Cannabis and Me'[9][10][11][12]

More recently, Prof Glass has applied her expertise in G protein-coupled receptors to the forest pathogen, kauri dieback. In 2018, she received a grant from the Marsden Fund entitled "Applying human drug discovery approaches to kauri dieback"[13]

Selected works
  • Glass, M., R. L. M. Faull, and M. Dragunow. "Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain." Neuroscience 77, no. 2 (1997): 299-318.
  • Glass, Michelle, and Christian C. Felder. "Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor." Journal of Neuroscience 17, no. 14 (1997): 5327-5333.
  • Buckley, Nancy E., Kathleen L. McCoy, Éva Mezey, Tom Bonner, Anne Zimmer, Christian C. Felder, Michelle Glass, and Andreas Zimmer. "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor." European Journal of Pharmacology 396, no. 2-3 (2000): 141-149.
  • Glass, M., M. Dragunow, and R. L. M. Faull. "The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease." Neuroscience 97, no. 3 (2000): 505-519.
  • Felder, Christian C., and Michelle Glass. "Cannabinoid receptors and their endogenous agonists." Annual Review of Pharmacology and toxicology 38, no. 1 (1998): 179-200.
  • Kearn, Christopher S., Katherine Blake-Palmer, Emma Daniel, Ken Mackie, and Michelle Glass. "Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor crosstalk?." Molecular Pharmacology (2005).
  • Robson, Hunter, Rhiannon Braund, Michelle Glass, Janelle Ashton, Michael Tatley. "Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre." Clinical Toxicology (2020).

References
  1. https://www.otago.ac.nz/phal/people/profile/index.html?id=2996
  2. "Professor Michelle Glass - The University of Auckland". unidirectory.auckland.ac.nz.
  3. "Researchers split $53m fund". Stuff.
  4. "$157,000 to study cannabinoids' effect on brain cancer". 20 July 2016.
  5. "Demystifying synthetic cannabis". 10 August 2018.
  6. "Killer synthetic drug was never tested on humans". 16 September 2017.
  7. "Why is synthetic cannabis killing Kiwis more than anyone else in the world?" – via TVNZ.
  8. simon.collins@nzherald.co.nz, Simon Collins Education reporter, NZ Herald (29 July 2017). "Minister and drug expert: 'Tell us what's in killer synthetic cannabis'" – via www.nzherald.co.nz.
  9. "Med student's heartfelt medicinal marijuana documentary Mum, Cannabis and Me premieres". 8 September 2017.
  10. "Mum, Cannabis and Me documentary premier challenges medicinal cannabis use". Stuff.
  11. "Mum, cannabis and me to screen tomorrow".
  12. "Educational Docco World Premiere - 'Mum, Cannabis, And Me' - Scoop News". www.scoop.co.nz.
  13. "Royal Society Te Apārangi - Saving kauri with a human drug discovery approach". royalsociety.org.nz. Retrieved 18 January 2019.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.